Your session is about to expire
← Back to Search
Intraocular Lens
enVista MX60EF for Cataract
N/A
Waitlist Available
Research Sponsored by Bausch & Lomb Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 120 to day 180 after second eye implantation
Awards & highlights
Study Summary
This trial will test the safety and effectiveness of a new type of intraocular lens for people with cataracts.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 120 to day 180 after second eye implantation
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 120 to day 180 after second eye implantation
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Photopic monocular best-corrected distance visual acuity (BCDVA)
Photopic monocular distance-corrected intermediate visual acuity (DCIVA)
Photopic monocular distance-corrected near visual acuity (DCNVA)
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: enVista MX60EFExperimental Treatment1 Intervention
enVista MX60EF (trifocal) multifocal IOL (MIOL)
Group II: enVista MX60EActive Control1 Intervention
enVista MX60E monofocal IOL
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
enVista MX60EF
2018
N/A
~510
Find a Location
Who is running the clinical trial?
Bausch & Lomb IncorporatedLead Sponsor
251 Previous Clinical Trials
56,918 Total Patients Enrolled
47 Trials studying Cataract
15,502 Patients Enrolled for Cataract
Anya LoncaricStudy DirectorBausch health companies
39 Previous Clinical Trials
20,330 Total Patients Enrolled
5 Trials studying Cataract
1,751 Patients Enrolled for Cataract
Share this study with friends
Copy Link
Messenger